Previous 10 | Next 10 |
It's been tough-going for international investors. A stronger U.S. economy has led to more investment dollars flowing to U.S. equities than foreign companies, resulting in significant under-performance for foreign issues. For instance, the iShares MSCI EAFE ETF ( EFA ) has lagged the SPDR S&am...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S. Food and Drug Administration (USFDA) via...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multiple-Dose Vials, the therapeutic generic equiv...
Dr. Reddy's Laboratories Ltd (RDY) Q2 2020 Earnings Conference Call November 01, 2019, 09:00 ET Company Participants Amit Agarwal - Director, Finance, FP&A and IR Saumen Chakraborty - President & CFO Erez Israeli - CEO Conference Call Participants Prakash Agarwal -...
Dr. Reddy's ( RDY ) Q2 results : Revenues: $680M (+26.4%). More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Earnings news and commentary, Read more ...
Dr. Reddy's (NYSE: RDY ): Q2 EPS of $0.93 may not be comparable to consensus of $0.49. Revenue of $680M (+26.4% Y/Y) beats by $83.43M . Shares down 1% in India. Press Release More news on: Dr. Reddy's Laboratories Limited, Earnings news and commentary, Healthcare stock...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards (IFRS). Commenting on the results, Co-Chairman and ...
The opioid epidemic is a complex problem with no simple or ideal solution. The Centers for Disease Control and Prevention (CDC) estimates that 47,600 Americans died from opioid-related overdoses in 2017. One study published earlier this year by Massachusetts General Hospital estimates that 700,0...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...